Compare · CBLL vs MDT
CBLL vs MDT
Side-by-side comparison of CeriBell Inc. (CBLL) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLL and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $103.20B, about 146.3x CBLL ($705.4M).
- Over the past year, CBLL is up 8.0% and MDT is down 8.6% - CBLL leads by 16.6 points.
- MDT has been more active in the news (20 items in the past 4 weeks vs 15 for CBLL).
- MDT has more recent analyst coverage (25 ratings vs 8 for CBLL).
- Company
- CeriBell Inc.
- Medtronic plc.
- Price
- $18.56+0.30%
- $80.38+0.26%
- Market cap
- $705.4M
- $103.20B
- 1M return
- +12.76%
- +4.44%
- 1Y return
- +7.97%
- -8.59%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 15
- 20
- Recent ratings
- 8
- 25
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest CBLL
- Director Taylor Joseph Michael sold $101,255 worth of shares (5,500 units at $18.41), decreasing direct ownership by 8% to 61,573 units (SEC Form 4)
- President and CEO Chao Xingjuan sold $714,870 worth of shares (39,000 units at $18.33) as part of a pre-agreed trading plan and exercised 25,000 shares at a strike of $4.70, decreasing direct ownership by 2% to 816,317 units (SEC Form 4)
- Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes
- Director Tammenoms Bakker Juliet was granted 7,838 shares, increasing direct ownership by 51% to 23,284 units (SEC Form 4)
- Director Parvizi Josef was granted 7,838 shares, increasing direct ownership by 51% to 23,284 units (SEC Form 4)
- Director Rogers Erica J. was granted 7,838 shares, increasing direct ownership by 31% to 33,054 units (SEC Form 4)
- Director Burke William W was granted 7,838 shares, increasing direct ownership by 45% to 25,229 units (SEC Form 4)
- Director Taylor Joseph Michael was granted 7,838 shares, increasing direct ownership by 13% to 67,073 units (SEC Form 4)
- Director Robertson Rebecca B was granted 7,838 shares, increasing direct ownership by 42% to 26,587 units (SEC Form 4)
- CeriBell Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest MDT
- Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
- EVP & President Cardiovascular Kiil Harry Skip sold $336,965 worth of Ordinary Shares (4,189 units at $80.44), decreasing direct ownership by 10% to 37,227 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 6,817 units of Ordinary Shares, decreasing direct ownership by 14% to 41,416 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey covered exercise/tax liability with 41,936 units of Ordinary Shares, decreasing direct ownership by 12% to 301,163 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 7,471 units of Ordinary Shares, decreasing direct ownership by 11% to 63,122 units (SEC Form 4)
- SVP, Chief HR Officer Walter Matthew R. covered exercise/tax liability with 2,840 units of Ordinary Shares, decreasing direct ownership by 7% to 38,689 units (SEC Form 4)
- Chief Accounting Officer Blomquist Denise L. covered exercise/tax liability with 237 units of Ordinary Shares, decreasing direct ownership by 2% to 14,737 units (SEC Form 4)
- Medtronic upgraded by BTIG Research with a new price target
- Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States
- Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens